Drug profile · INN
peginesatide acetate
OMONTYS
peginesatide acetate (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda. Route of administration: intravenous, subcutaneous. Current US regulatory status: approved.
Drug details — peginesatide acetate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS, SUBCUTANEOUS
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
peginesatide acetate (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda. Route of administration: intravenous, subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is peginesatide acetate?
peginesatide acetate (OMONTYS) is a erythropoietin receptor agonist. Associated with Takeda. Route of administration: intravenous, subcutaneous. Current US regulatory status: approved.
What is the brand name for peginesatide acetate?
OMONTYS is a marketed brand name for peginesatide acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of peginesatide acetate?
peginesatide acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.